Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Comparative, Open-Label, Randomized, Multicenter, China-Only Study to Investigate the Pharmacokinetics, Efficacy and Safety of Subcutaneous Rituximab Versus Intravenous Rituximab Both in Combination With CHOP in Previously Untreated Patients With CD20 Positive Diffuse Large B Cell Lymphoma

Next Previous
Trial Profile

A Phase II Comparative, Open-Label, Randomized, Multicenter, China-Only Study to Investigate the Pharmacokinetics, Efficacy and Safety of Subcutaneous Rituximab Versus Intravenous Rituximab Both in Combination With CHOP in Previously Untreated Patients With CD20 Positive Diffuse Large B Cell Lymphoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Rituximab (Primary) ; Vincristine (Primary) ; Antihistamines; Diphenhydramine; Paracetamol
  • Indications Diffuse large B cell lymphoma
  • Focus Pharmacokinetics
  • Sponsors Roche

Most Recent Events

  • 01 Apr 2025 Results evaluating pharmacokinetics, efficacy, and safety of subcutaneous versus intravenous rituximab published in the Leukemia and Lymphoma.
  • 15 Jul 2023 Primary endpoint has been met. (Ratio of serum SC rituximab trough concentration (Ctrough,SC) and serum IV rituximab trough concentration (Ctrough,IV) during Cycle 7)
  • 15 Jun 2023 Results presented at the 28th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top